A Study Comparing PF-06273340 Immediate Release Tablet, PF-06273340 Modified Release Tablets To PF-06273340 Oral Solution In The Fasted State. This Study Will Also Compare PF-06273340 Modified Release Tablets In Fasted And Fed State

A Phase 1, Open Label, Randomized, Single Dose, 5 Period Crossover Relative Bioavailability Study In Healthy Volunteers Evaluating Spray Dried Dispersion (SDD) Immediate Release (IR) PF-06273340 Tablet, Two SDD Modified Release (MR) Matrix Tablets In Comparison With PF-06273340 Oral Solution, Including Preliminary Assessment Of Food Effect

The primary purpose of this study is to estimate the relative bioavailability and food effect of PF-06273340 tablets.

Study Overview

• Status: Completed
• Conditions: Healthy
• Intervention / Treatment: Drug: PF-06273340; Drug: PF-06273340; Drug: PF-06273340; Drug: PF-06273340; Drug: PF-06273340; Drug: PF-06273340

• Study Type: Interventional
• Enrollment (Actual): 12
• Phase: Phase 1

Contacts and Locations

Study Locations

• Singapore
  • Singapore, Singapore, 188770
    • Pfizer Investigational Site

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 21 years to 55 years (Adult)
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Healthy male and/or female subjects of non-child bearing potential, between the ages of 21 and 55 years, inclusive (Healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, full physical examination, including blood pressure and pulse rate measurement, 12-lead ECG and clinical laboratory tests).
• Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight >50 kg (110 lbs).
• An informed consent document signed and dated by the subject.
• Subjects who are willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures

Exclusion Criteria:

• Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing).
• Any condition possibly affecting drug absorption (eg, gastrectomy).
• A positive urine drug screen.
• History of regular alcohol consumption exceeding 14 drinks/week for females or 21 drinks/week for males (1 drink = 5 ounces (150 mL) of wine or 12 ounces (360 mL) of beer or 1.5 ounces (45 mL) of hard liquor) within 6 months of Screening.
• Use of tobacco- or nicotine-containing products in excess of the equivalent of 5 cigarettes per day.
• Treatment with an investigational drug within 30 days (or as determined by the local requirement, whichever is longer) or 5 half-lives preceding the first dose of study medication.
• Screening supine blood pressure >=140 mm Hg (systolic) or >=90 mm Hg (diastolic), on a single measurement (confirmed by a single repeat, if necessary) following at least 5 minutes of rest.
• Evidence or history of orthostatic hypotension.
• 12-lead ECG demonstrating QTc >450 or a QRS interval >120 msec at Screening. If QTc exceeds 450 msec, or QRS exceeds 120 msec, the ECG should be repeated two more times and the average of the three QTc values should be used to determine the subject's eligibility.
• Pregnant or nursing females; females of childbearing potential, including those with tubal ligation.
• Use of prescription or nonprescription drugs, vitamins and dietary supplements within 7 days or 5 half-lives (whichever is longer) prior to the first dose of study medication. Herbal supplements must be discontinued 28 days prior to the first dose of study medication. As an exception, acetaminophen/paracetamol may be used at doses of <=1 g/day. Limited use of non-prescription medications that are not believed to affect subject safety or the overall results of the study may be permitted on a case-by-case basis following approval by the sponsor.
• Blood donation (excluding plasma donations) of approximately 1 pint (500 mL) or more within 56 days prior to dosing.
• History of sensitivity to heparin or heparin-induced thrombocytopenia.
• Unwilling or unable to comply with the Lifestyle guidelines described in this protocol.
• Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for entry into this study.
• Subjects who are investigational site staff members or relatives of those site staff members or subjects who are Pfizer employees directly involved in the conduct of the trial.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Crossover Assignment
• Masking: None (Open Label)

Number of Arms

6

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: PF-06273340 Oral Solution Fasted	Drug: PF-06273340; Oral solution, single dose, fasted; Drug: PF-06273340; Immediate Release Tablet, single dose, fasted; Drug: PF-06273340; Modified Release Tablet (short duration, MR1), single dose, fasted; Drug: PF-06273340; Modified Release Tablet (long duration, MR2), single dose, fasted; Drug: PF-06273340; Modified Release Tablet (short duration, MR1), single dose, fed; Drug: PF-06273340; Modified Release Tablet (long duration, MR2), single dose, fed
Experimental: PF-06273340 Immediate Release Tablet Fasted	Drug: PF-06273340; Oral solution, single dose, fasted; Drug: PF-06273340; Immediate Release Tablet, single dose, fasted; Drug: PF-06273340; Modified Release Tablet (short duration, MR1), single dose, fasted; Drug: PF-06273340; Modified Release Tablet (long duration, MR2), single dose, fasted; Drug: PF-06273340; Modified Release Tablet (short duration, MR1), single dose, fed; Drug: PF-06273340; Modified Release Tablet (long duration, MR2), single dose, fed
Experimental: PF-06273340 Modified Release (MR1) Tablet Fasted	Drug: PF-06273340; Oral solution, single dose, fasted; Drug: PF-06273340; Immediate Release Tablet, single dose, fasted; Drug: PF-06273340; Modified Release Tablet (short duration, MR1), single dose, fasted; Drug: PF-06273340; Modified Release Tablet (long duration, MR2), single dose, fasted; Drug: PF-06273340; Modified Release Tablet (short duration, MR1), single dose, fed; Drug: PF-06273340; Modified Release Tablet (long duration, MR2), single dose, fed
Experimental: PF-06273340 Modified Release (MR2) Tablet Fasted	Drug: PF-06273340; Oral solution, single dose, fasted; Drug: PF-06273340; Immediate Release Tablet, single dose, fasted; Drug: PF-06273340; Modified Release Tablet (short duration, MR1), single dose, fasted; Drug: PF-06273340; Modified Release Tablet (long duration, MR2), single dose, fasted; Drug: PF-06273340; Modified Release Tablet (short duration, MR1), single dose, fed; Drug: PF-06273340; Modified Release Tablet (long duration, MR2), single dose, fed
Experimental: PF-06273340 Modified Release (MR1) Tablet Fed	Drug: PF-06273340; Oral solution, single dose, fasted; Drug: PF-06273340; Immediate Release Tablet, single dose, fasted; Drug: PF-06273340; Modified Release Tablet (short duration, MR1), single dose, fasted; Drug: PF-06273340; Modified Release Tablet (long duration, MR2), single dose, fasted; Drug: PF-06273340; Modified Release Tablet (short duration, MR1), single dose, fed; Drug: PF-06273340; Modified Release Tablet (long duration, MR2), single dose, fed
Experimental: PF-06273340 Modified Release (MR2) Tablet Fed	Drug: PF-06273340; Oral solution, single dose, fasted; Drug: PF-06273340; Immediate Release Tablet, single dose, fasted; Drug: PF-06273340; Modified Release Tablet (short duration, MR1), single dose, fasted; Drug: PF-06273340; Modified Release Tablet (long duration, MR2), single dose, fasted; Drug: PF-06273340; Modified Release Tablet (short duration, MR1), single dose, fed; Drug: PF-06273340; Modified Release Tablet (long duration, MR2), single dose, fed

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Maximum Observed Plasma Concentration (Cmax)	up to 48 h post dose
Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast)	up to 48 h post dose
Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - 8)]	up to 48 h post dose
Elimination half life	up to 48 h post dose
Time to Reach Maximum Observed Plasma Concentration (Tmax)	up to 48 h post dose

Collaborators and Investigators

• Sponsor: Pfizer

Publications and helpful links

Helpful Links

• To obtain contact information for a study center near you, click here.

Study record dates

Study Major Dates

• Study Start: November 1, 2012
• Primary Completion (Actual): January 1, 2013
• Study Completion (Actual): January 1, 2013

Study Registration Dates

• First Submitted: October 11, 2012
• First Submitted That Met QC Criteria: October 11, 2012
• First Posted (Estimate): October 15, 2012

Study Record Updates

• Last Update Posted (Estimate): January 24, 2013
• Last Update Submitted That Met QC Criteria: January 23, 2013
• Last Verified: January 1, 2013

More Information

Terms related to this study

• Keywords: Pain
• Other Study ID Numbers: B5261003